EQ

Equillium, Inc.

0.73 USD
+0.02 (+2.92%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Equillium, Inc. stock is down -52.96% since 30 days ago. The next earnings date is Aug 7, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 16.67% of the previous 5 June’s closed higher than May. 100% of analysts rate it a buy.

About Equillium, Inc.

Equillium, Inc. develops and sells products to treat severe autoimmune and inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6.